AI assistant
Lyell Immunopharma, Inc. — Director's Dealing 2025
Jun 11, 2025
33362_dirs_2025-06-11_c62ea72e-afcd-4208-b3a4-9038f13c2bac.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-06-09
Reporting Person: Shook David (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-09 | Common Stock | A | 21900 | — | Acquired | 21900 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-09 | Option (right to buy) | $12.47 | A | 43750 | Acquired | 2035-06-08 | Common Stock (43750) | Direct |
Footnotes
F1: Represents restricted stock units granted under the Issuer's 2021 Equity Incentive Plan ("RSUs"). 25% of the total shares subject to the RSUs will vest on June 9, 2026, and an additional 1/16th of the total shares subject to the RSUs per quarter thereafter, subject to the reporting person providing service through the applicable vesting date.
F2: 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.